Thomas Triomphe leads Sanofi’s vaccines business unit, which encompasses R&D and commercial operations and drives the teams’ commitment to prevention against infectious diseases. The Sanofi portfolio currently includes seasonal influenza vaccines, pediatric combinations, adolescent and adult boosters, and meningitis and travel/endemic vaccines, as well as ongoing development of the first preventive intervention against RSV for all infants, RSV vaccines for toddlers, improved vaccines against pneumococcal infections and yellow fever, and first-in-class vaccines against chlamydia infections and moderate to severe acne. Thomas joined Sanofi in 2004 and has held various positions at country, regional, and global levels.